(2023)
Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
CLINICAL CANCER RESEARCH.
23,
1689
(2023)
Dosimetric comparison between RapidArc and HyperArc in hippocampal-sparing whole-brain radiotherapy with a simultaneous integrated boost.
MEDICAL DOSIMETRY.
x,
x
(2023)
Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer.
JOURNAL OF CLINICAL MEDICINE.
12,
9
(2023)
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
8
(2023)
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
CANCER RESEARCH AND TREATMENT.
55,
4
(2022)
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.
CANCERS.
14,
14
(2022)
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
JTO Clinical and Research Reports.
3,
6
(2022)
Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.
CANCERS.
14,
8
(2022)
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
ESMO OPEN.
7,
2
(2022)
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial.
JOURNAL OF CANCER.
13,
3
(2021)
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
CLINICAL CANCER RESEARCH.
27,
19
(2021)
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
EUROPEAN JOURNAL OF CANCER.
157,
2021
(2021)
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
13,
1
(2021)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin postoperative chemoradiation with S-1 oxaliplatin in patients with node-positive gastric cancer after D2 resection the ARTIST 2 trial.
ANNALS OF ONCOLOGY.
32,
3
(2021)
Relationship between heavy metal exposure and type 2 diabetes: a large-scale retrospective cohort study using occupational health examinations.
BMJ OPEN.
11,
3
(2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
LANCET ONCOLOGY.
22,
1
(2020)
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
LUNG CANCER.
149,
1
(2020)
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
ONCOLOGIST.
25,
1
(2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
LANCET.
394,
10212
학술회의논문
(2020)
Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN.
ESMO ASIA.
싱가포르
(2016)
A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study.
ESMO ASIA 2016.
싱가포르
(2016)
Chemotherapy versus best supportive care in patients with advanced biliary tract carcinoma: A propensity score-matched analysis..
2016 Gastrointestinal Cancers Symposium.
미국
(2014)
Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS)..
2014 ASCO annual meeting.
미국